AGENDA
Maxillo-ethmoidal Complex and Anterior Skull Base
Opening Ceremony
Lecture:
Lecture: 9TNM of the larynx and its future role in prognostication between obsolescence and renovation
Welcome Reception
Masterclass in TOLM
Masterclass in OPHL
Limits of TOLM
Limits of OPHL
DELMAR – larynx Laryngeal cancer in the NEW era of non-surgical organ preservation
TORS supraglottic laryngectomy: pro and cons ?
TORS for oropharyngeal cancer: outcomes, limits and scope on the future.
Neoadjuvant CT before TORS in oro/hypo pharyngeal cancer Update on Exoscopic Surgery with a focus on the role of the exoscope among the new minimally invasive technologies for oropharyngeal cancer surgery.
Evidence-based guideline diagnosis, treatment, prevention and aftercare of oropharyngeal and hypopharyngeal carcinoma.
Pharyngeal cancer in the HPV and robotic era
Pharynx Cancer Masterclass.
TORS supraglottic laryngectomy: pro and cons ?
TORS for oropharyngeal cancer: outcomes, limits and scope on the future.
Neoadjuvant CT before TORS in oro/hypo pharyngeal cancer
Update on Exoscopic Surgery with a focus on the role of the exoscope among the new minimally invasive technologies for oropharyngeal cancer surgery.
Evidence-based guideline diagnosis, treatment, prevention and aftercare of oropharyngeal and hypopharyngeal carcinoma.
Pharyngeal cancer in the HPV and robotic era.
RESET ready for safe cancer treatment
Introduction: Prehabilitation
Nutrition
Pharmacotherapy
Physiotherapy
Psychological support
Post-RT/CRT supplementation in outpatient HNC Ready-to-use regimens: antibiotics, PPIs, mucosal protection, mucolytics.
Immunotherapy; management of immune-mediated sinusitis
1.GPA
2.Churg–Strauss syndrome
3.IgE4-dependent disorders
1.Immunological processes: surgical vs systemic pathways
2.Cysts: surgery vs observation
3.Inflammatory tumours: diagnostic challenges.
Proton therapy – indications and limitations.
Should tracheotomy be avoided prior to laryngeal cancer treatment (LC), and why?
2.Primary vs secondary implantation
3.Voice prostheses in salvage TL
4.Project outcomes
Antibiotic therapy in hospitalized laryngeal cancer patients (TL vs TOLM differences)
Changing epidemiology of HNC
1. Radiation Oncologist
2. Surgeon
3. Medical oncologist
1. Radiation Oncologist
2. Surgeon
3. Medical oncologist
Leucoplakia – carcinogenesis and biofilm. Predictive signature of dysplastic transformation in premalignant laryngeal epithelial lesions modulated by microbiota.
Is pre-treatment hearing aid fitting an urgent need in oncology patients?
Immunotherapy in HNC:
1.Ongoing clinical trials.
2.Qualification criteria.
3.Patient preparation.
4.Treatment-related complications.
Perspectives: Combined immunotherapy and modern surgery – second-line HNC treatment.
Challenges during HNC MDT discussions: decision ownership.
Special populations and cases:
1. Elderly patients
2. MPT decision-making
3. T3 larynx
4. T2 pharynx
Halo, Teleradiology! Minimum diagnostic requirements for MDT (MRI, CT, US).
Clinical vs radiological vs surgical vs radiation perspectives.
“Onco” diets – facts vs myths?
Pathology for all:
No oncology without pathology
1.Cost and reimbursement pitfalls.
2.Handling large specimens.
3.Micro-specimen preparation.
4.DELMAR – European consensus on margins in organ preservation techniques
Patient-centred questions:
1.Diet after total laryngectomy.
2.Diet after oral/pharyngeal surgery.
3.Salivary gland diet – controversies.
Referral of HNC patients for genetic counselling.
Phonosurgery in oncology:
1.Augmentation after cordectomy.
2.Reinnervation after strumectomy.
3.Decannulation decision-making.
YO
Expectations from senior clinicians in:
1.Clinical training.
2.Ward interactions.
3.Scientific development.
The best FO
The best CR